Allison Wheeler, MD, delves into the complexities of prophylaxis for mild to moderate hemophilia A cases, exploring a patient-centric approach, situational prophylaxis during high-risk activities, and ...

Early prophylaxis reduces bone loss in haemophilia, while delayed or absent treatment increases osteoporosis risk.

Understand key factors influencing hemophilia A treatment decisions and explore the impact of prophylactic vs on-demand therapy on efficacy, safety, and patient outcomes, including joint health, ...

Treatment Considerations Additional survey results indicate a need for more frequent and transparent conversations around treatment options, with 65% of patients surveyed feeling like they still haven ...

Please provide your email address to receive an email when new articles are posted on . The monoclonal antibody significantly reduced both treated spontaneous and traumatic bleeds among individuals ...

Please provide your email address to receive an email when new articles are posted on . Patients who received prophylactic concizumab had a mean overall annualized bleeding rate of zero compared with ...

Pfizer gets FDA priority review for Hympavzi to treat children 6-11 with hemophilia A or B, expanding current U.S. approvals.

Prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) significantly reduced the risk for serious infections by approximately 50% in patients with antineutrophil cytoplasmic antibody ...